Study S003397

Phase 2/3, Randomized, Double-blind, Placebo- and Active Comparator-controlled, Parallel, Multicenter Study to Determine Safety and Efficacy of Metaglidasen in Treatment of Type 2 Diabetes Suboptimally Controlled on Insulin

ClinicalTrials.gov record

Registration

Registration: NCT00353587
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 396
Start: 2006-05
Primary completion: 2007-11
Lead sponsor: Gilead Sciences
Conditions: Type 2 Diabetes
Interventions: DRUG:MBX-102; DRUG:Placebo; DRUG:Actos
Results posted: FALSE

Registered primary outcomes

Evaluate effects of MBX-102 administered orally at doses of 200, 400 and 600 mg daily for 16 weeks, on glucose control, as measured by HbA1c []
Evaluate safety of MBX-102 with particular emphasis on endpoints of weight gain and edema []

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.